A new drug claims to reduce the number of migraines an individual suffers. In a study on the effectiveness of the new drug, 50 subjects were given the new drug and another 50 subjects were given a placebo. At the end of the 6-month study, the group given the new drug reported an average of 1.3 migraines a week. The group given the placebo reported an average of 2.5 migraines a week. The data from the study are rerandomized 10 times. The difference of the means from rerandomization are 1.2, 3.4, 1.8, 1.3, 1.1, 0.9, 2.5, 0.7, 1.1, and 0.9.